Dorsey Wright & Associates Purchases 3,375 Shares of Ascendis Pharma A/S $ASND

Dorsey Wright & Associates grew its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 39.7% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 11,879 shares of the biotechnology company’s stock after purchasing an additional 3,375 shares during the quarter. Dorsey Wright & Associates’ holdings in Ascendis Pharma A/S were worth $2,717,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ASND. Advisory Services Network LLC bought a new position in Ascendis Pharma A/S in the 3rd quarter worth approximately $26,000. Arax Advisory Partners increased its position in shares of Ascendis Pharma A/S by 212.2% during the 4th quarter. Arax Advisory Partners now owns 153 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 104 shares in the last quarter. Leonteq Securities AG acquired a new stake in Ascendis Pharma A/S during the 4th quarter valued at $36,000. Caitong International Asset Management Co. Ltd acquired a new stake in Ascendis Pharma A/S in the 4th quarter valued at about $42,000. Finally, Global Retirement Partners LLC lifted its holdings in Ascendis Pharma A/S by 111.9% during the 4th quarter. Global Retirement Partners LLC now owns 214 shares of the biotechnology company’s stock worth $46,000 after buying an additional 113 shares in the last quarter.

Insider Buying and Selling at Ascendis Pharma A/S

In other news, insider Flemming Steen Jensen sold 19,460 shares of Ascendis Pharma A/S stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $238.49, for a total transaction of $4,641,015.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Jean Jacques Bienaime bought 400 shares of the stock in a transaction dated Tuesday, May 26th. The stock was purchased at an average price of $237.80 per share, with a total value of $95,120.00. Following the acquisition, the director owned 400 shares of the company’s stock, valued at $95,120. The trade was a ? increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 40.00% of the stock is owned by insiders.

Ascendis Pharma A/S Stock Performance

NASDAQ:ASND opened at $261.00 on Friday. The company has a market cap of $16.28 billion, a price-to-earnings ratio of 30.10 and a beta of 0.37. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.72 and a current ratio of 1.00. Ascendis Pharma A/S has a fifty-two week low of $160.86 and a fifty-two week high of $282.15. The stock has a fifty day moving average price of $242.89 and a 200-day moving average price of $232.02.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its earnings results on Thursday, May 7th. The biotechnology company reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of $0.21 by $0.11. The business had revenue of $285.45 million during the quarter, compared to analyst estimates of $362.47 million. As a group, equities analysts anticipate that Ascendis Pharma A/S will post 4.63 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have commented on ASND. Citigroup began coverage on shares of Ascendis Pharma A/S in a research report on Monday, May 18th. They set a “buy” rating and a $355.00 target price for the company. Wells Fargo & Company reduced their price target on shares of Ascendis Pharma A/S from $330.00 to $326.00 and set an “overweight” rating for the company in a report on Friday, May 8th. Barclays increased their price objective on Ascendis Pharma A/S from $342.00 to $345.00 and gave the stock an “overweight” rating in a report on Monday, May 11th. Bank of America raised their target price on shares of Ascendis Pharma A/S from $262.00 to $292.00 and gave the company a “buy” rating in a research report on Thursday, April 16th. Finally, Evercore reaffirmed an “outperform” rating and set a $329.00 price target on shares of Ascendis Pharma A/S in a research report on Friday, May 15th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, Ascendis Pharma A/S has a consensus rating of “Buy” and an average price target of $295.67.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S is a Denmark?based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long?acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once?weekly growth hormone therapy approved by the U.S.